All In Biotech

Drug Trial Radar · NCT00853970

Efficacy Study of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery

Last checked: Nov 20, 2026Latest source record: Jan 25, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 299 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

299

Actual

Start

Feb 2009

Primary completion

Sep 2009

Study completion Dec 2009

Sponsor

Lead sponsor
Bausch & Lomb IncorporatedIndustry
Sponsor type
Industry
First posted
Mar 2, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Efficacy study of Bromfenac Ophthalmic Solution in cataract surgery

Conditions

  • Pain
  • Inflammation

Interventions

  • Bromfenac Ophthalmic SolutionDrug

    sterile ophthalmic solution

  • Placebo ComparatorDrug

    sterile ophthalmic solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Summed Ocular Inflammation Score (SOIS) of ZeroTime frame: Day 15 (Primary Endpoint)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • ISTA Pharmaceuticals, Inc.

    Irvine, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.